Welcome from the Program Director
Thank you for taking time to learn more about MU's Master of Science in Pharmacogenomics (MS in PGx) Program.
Pharmacogenomics, the study of a patient’s response to medications relative to their genetics is a rapidly expanding component of precision medicine. The ability to look at an individual’s DNA and use that information to guide drug and/or drug dose selection can lead to more successful treatment, and reduce adverse drug reactions.
Manchester University has recognized the need for education of applied scientists in PGx. In doing so, the University has designed a rigorous, innovative MS in PGx Program. The program underwent an extensive application process and is approved by the Higher Learning Commission.
The mission of the MS in PGx program is to prepare individuals with the skills to excel as applied scientists in the pharmacogenetic/pharmacogenomic and pharmaceutical industries.
The following are the objectives of the program:
- To enable students to perform a full range of testing in the contemporary pharmacogenomics/biomolecular laboratory encompassing pre-analytical, analytical, and post-analytical components;
- To prepare students to interpret genetic testing results to facilitate optimization of drug selection by clinicians;
- To educate students on the ethical applications of genetic testing results.
It is clear that medicine is changing and Manchester University, through its MS in PGx Program is helping to lead that change. Upon completion of the program, it is our students that will help move individuals to better health. Thank you for visiting the Manchester MS in PGx website and for your interest in the program!
We invite you to explore the information presented here and contact us with any questions by emailing PGx@manchester.edu or by calling our Office of Admissions at 800-852-3648.
David F. Kisor, BS, PharmD
Professor and Chair, Pharmaceutical Sciences
Director, Master of Science in Pharmacogenomics Program